Suppr超能文献

相似文献

1
Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients.
J Clin Microbiol. 2022 Feb 16;60(2):e0016121. doi: 10.1128/JCM.00161-21. Epub 2021 Jun 16.
3
Fecal Microbiota Transplant in Pediatric Solid Organ Transplant Recipients.
Transplantation. 2023 Sep 1;107(9):2073-2077. doi: 10.1097/TP.0000000000004656. Epub 2023 May 22.
7
Fecal Microbiota Transplant for Clostridioides Difficile Infection Is Safe and Efficacious in an Immunocompromised Cohort.
Dig Dis Sci. 2022 Oct;67(10):4866-4873. doi: 10.1007/s10620-021-07347-x. Epub 2022 Jan 9.

引用本文的文献

1
Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection.
Pathogens. 2025 Jul 30;14(8):747. doi: 10.3390/pathogens14080747.
2
Microbiome Therapeutics for Clostridioides difficile Infection.
Infect Dis Clin North Am. 2025 Aug 11. doi: 10.1016/j.idc.2025.07.007.
3
Fecal microbiota transplantation: a tale of two regulatory pathways.
Gut Microbes. 2025 Dec;17(1):2493901. doi: 10.1080/19490976.2025.2493901. Epub 2025 Apr 29.
4
Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.
Front Microbiol. 2025 Mar 25;16:1556827. doi: 10.3389/fmicb.2025.1556827. eCollection 2025.
6
Campylobacter Infection Introduced Following Fecal Microbiota Transplantation.
Cureus. 2024 Jun 17;16(6):e62541. doi: 10.7759/cureus.62541. eCollection 2024 Jun.
7
The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.
Clin Infect Dis. 2023 Oct 16;77(Suppl 4):S331-S335. doi: 10.1093/cid/ciad532.
8
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
BioDrugs. 2023 Nov;37(6):757-773. doi: 10.1007/s40259-023-00617-2. Epub 2023 Jul 26.
9
Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients.
J Pediatr Gastroenterol Nutr. 2023 Apr 1;76(4):440-446. doi: 10.1097/MPG.0000000000003714. Epub 2023 Jan 31.
10
The contribution of the gut-liver axis to the immune signaling pathway of NAFLD.
Front Immunol. 2022 Aug 31;13:968799. doi: 10.3389/fimmu.2022.968799. eCollection 2022.

本文引用的文献

1
The journey towards safely restarting faecal microbiota transplantation services in the UK during the COVID-19 era.
Lancet Microbe. 2021 Apr;2(4):e133-e134. doi: 10.1016/S2666-5247(21)00036-7. Epub 2021 Feb 19.
4
Shiga Toxin-Producing Escherichia coli Transmission via Fecal Microbiota Transplant.
Clin Infect Dis. 2021 Jun 1;72(11):e876-e880. doi: 10.1093/cid/ciaa1486.
5
First microbiome-based drug clears phase III, in clinical trial turnaround.
Nat Rev Drug Discov. 2020 Oct;19(10):655-656. doi: 10.1038/d41573-020-00163-4.
6
A stool test in patients with active ulcerative colitis helps exclude cytomegalovirus disease.
Scand J Gastroenterol. 2020 Jun;55(6):664-670. doi: 10.1080/00365521.2020.1771760. Epub 2020 Jun 19.
7
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification.
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):642-643. doi: 10.1016/S2468-1253(20)30124-2. Epub 2020 Apr 22.
9
COVID-19: faecal-oral transmission?
Nat Rev Gastroenterol Hepatol. 2020 May;17(5):259. doi: 10.1038/s41575-020-0295-7.
10
Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug.
United European Gastroenterol J. 2019 Dec;7(10):1408-1410. doi: 10.1177/2050640619887579. Epub 2019 Nov 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验